The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Oral Rigosertib for Squamous Cell Carcinoma
Official Title: A Phase II Study of Oral Rigosertib in Patients With Relapsed or Metastatic, Platinum-resistant, Human Papillomavirus Positive or Negative Squamous Cell Carcinoma
Study ID: NCT01807546
Brief Summary: The primary objective of this study is to determine if tumors in patients with papillomavirus (HPV) positive or negative squamous cell carcinoma (SCC) that no longer responds to standard therapy will decrease in size following treatment with the investigational drug, rigosertib sodium (ON 01910.Na). A secondary objective is to determine if treatment with rigosertib causes any side effects. Rigosertib is an investigational drug, which means that it has not been approved by the U.S. Food and Drug Administration (FDA) to treat any diseases. We are studying rigosertib as a new anticancer drug. Tests that we have done in the laboratory suggest that rigosertib works by blocking cell division in cancer cells and causing them to die.
Detailed Description: This will be a multicenter, Phase II study to evaluate the safety and efficacy of oral rigosertib in patients with relapsed or metastatic squamous cell carinoma (SCC) who previously received platinum-based chemotherapy and/or chemo-radiation therapy. Only patients with head and neck squamous cell carinoma (HNSCC), non-small cell lung SCC, skin SCC, cervical SCC, penile SCC, anal SCC or esophageal SCC will be enrolled in the study. Patients will be administered rigosertib capsules at a dose of 560 mg BID on days 1 to 14 of a 21-day cycle. Patients will be enrolled in 2 cohorts based on HPV test results: * Cohort 1 will include up to 40 patients with human papillomavirus (HPV)-positive SCC, of which approximately 30 patients will have HNSCC, and approximately 10 patients with SCC of another origin (eg, cervix, anal, penile); * Cohort 2 will include up to 40 patients with HPV-negative SCC, of which approximately 30 patients will have HNSCC, and approximately 10 patients with SCC of another origin (eg, lung, skin, esophageal). Patients will be evaluated for progression after completing 3 cycles of therapy and every 3 cycles thereafter. Patients with stable disease (SD) or better, based on revised Response Criteria in Solid Tumors (mRECIST) 1.1, will receive repeated cycles of treatment on a 21-day cycle schedule until disease progression, development of unacceptable toxicity, or withdrawal of consent. Patients with progressive disease (PD) but who, in the opinion of the Investigator, appear to be deriving clinical benefit, may continue on study with a planned disease reassessment after one further cycle of therapy. Should the patient have SD or PR at this reassessment, s/he may continue on study, with subsequent reassessments every 3 cycles. Following discontinuation of rigosertib treatment, patients' mortality status will be assessed every 3 months.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Stanford Cancer Institute, Stanford, California, United States
University of Colorado School of Medicine, Aurora, Colorado, United States
Denver VA Medical Center-ECHCS, Denver, Colorado, United States
University of Michigan Health System, Ann Arbor, Michigan, United States
Veterans Administration New Jersey Health Care System, East Orange, New Jersey, United States
Mount Sinai Medical Center, New York, New York, United States
Montefiore Medical Center, The Bronx, New York, United States
Ohio State University, James Cancer Hospital, Columbus, Ohio, United States
University of Pennslvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States
Mary Crowley Cancer Research Center, Dallas, Texas, United States
Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
Blue Ridge Cancer Care, Salem, Virginia, United States
Name: Michael Kurman, MD
Affiliation: Traws Pharma, Inc.
Role: STUDY_DIRECTOR